Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
- C. W. Olanow, C. Götz, +8 authors T. Freeman
- Medicine
- Annals of neurology
- 1 September 2003
Thirty‐four patients with advanced Parkinson's disease participated in a prospective 24‐month double‐blind, placebo‐controlled trial of fetal nigral transplantation. Patients were randomized to… Expand
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein
- L. Ozelius, J. Hewett, +12 authors X. Breakefield
- Biology, Medicine
- Nature Genetics
- 1 September 1997
Early-onset torsion dystonia is a movement disorder, characterized by twisting muscle contractures, that begins in childhood. Symptoms are believed to result from altered neuronal communication in… Expand
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
- F. Cruz, S. Herschorn, +6 authors C. Haag-Molkenteller
- Medicine
- European urology
- 1 October 2011
BACKGROUND
Neurogenic detrusor overactivity (NDO) frequently results in urinary incontinence (UI) which impairs quality of life (QOL) and puts the upper urinary tract at risk.
OBJECTIVE
To assess… Expand
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program
(Headache 2010;50:921‐936)
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
- B. Schurch, M. de Sèze, +8 authors M. Brin
- Medicine
- The Journal of urology
- 2005
PURPOSE
We determined the safety and efficacy of each of 2 doses of botulinum toxin type A (BTX-A) (200 or 300 U BOTOX) injected into the detrusor for urinary incontinence caused by neurogenic… Expand
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
- D. Ginsberg, A. Gousse, +6 authors C. Haag-Molkenteller
- Medicine
- The Journal of urology
- 1 June 2012
PURPOSE
We assessed the efficacy, safety and effects on quality of life of onabotulinumtoxinA in patients with neurogenic detrusor overactivity.
MATERIALS AND METHODS
In this 52-week,… Expand
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
- W. Koller, C. W. Olanow, +16 authors M. Brin
- Medicine
- The New England journal of medicine
- 21 January 1993
BACKGROUND AND METHODS
In 1987 we began a multicenter controlled clinical trial of deprenyl (a monoamine oxidase inhibitor) and tocopherol (a component of vitamin E that traps free radicals) in the… Expand
Idiopathic cervical dystonia: Clinical characteristics
We reviewed detailed clinical features of 266 patients with idiopathic cervical dystonia, commonly called spasmodic torticollis. Mean age at onset (41 years), female‐to‐male ratio (1.9:1), clustering… Expand
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- S. Aurora, D. Dodick, +5 authors M. Brin
- Medicine
- Cephalalgia : an international journal of…
- 17 March 2010
Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine.… Expand
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- H. Diener, D. Dodick, +5 authors M. Brin
- Medicine
- Cephalalgia : an international journal of…
- 1 July 2010
Objectives: This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic migraine. Methods:… Expand